Adipocyte fatty-acid-binding protein, aP2 (encoded by Ap2), is a member of the intracellular fatty-acid-binding protein (FABP) family. Cytoplasmic FABPs are small proteins that are expressed in a highly tissue-specific manner and bind to fatty acids 1,2 . aP2 is primarily detected in adipose tissue and its expression is highly regulated during differentiation of adipocytes 3, 4 . Moreover, expression of Ap2 mRNA is transcriptionally controlled by fatty acids 5, 6 . Recent studies in aP2-deficient mice have shown that loss of this protein has a critical impact on several aspects of the metabolic syndrome. First, lack of aP2 provides significant protection from hyperinsulinemia and insulin resistance associated with dietary or genetic obesity 7, 8 . Second, aP2 contributes to improved systemic glucose and lipid metabolism in the setting of dietary or genetic obesity 7, 8 and alters the rate of adipocyte lipolysis 9,10 . As both insulin resistance and abnormal lipid metabolism are risk factors for cardiovascular disease, it is possible that aP2 influences the development of atherosclerosis by modulating these factors.
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Several lines of evidence indicate a striking overlap between the biology of adipocytes and macrophages. Genes that are critical in adipocytes, including those encoding transcription factors, cytokines, inflammatory molecules, fatty acid transporters and scavenger receptors, are also expressed in macrophages and have an important role in their biology 11 . For example, peroxisome-proliferator activated receptor-γ (PPAR-γ) is a member of the nuclear-receptor superfamily of ligand-activated transcription factors that regulates adipocyte development and glucose homeostasis. PPAR-γ is also expressed in activated monocyte/macrophages and might have a role in generating the inflammatory response and forming the foam cells associated with atherosclerotic lesions [12] [13] [14] [15] [16] ; however, the mechanisms for these functions are unclear. Interestingly, aP2 expression was recently revealed in human monocytes following stimulation with PPAR-γ activators 17 , and oxidized low-density lipoprotein has been reported to induce expression of aP2 in human THP-1 macrophages 18 . These observations indicate that expression of aP2 by macrophages might also influence foam-cell formation and thereby atherosclerotic processes, possibly through mechanisms independent of its metabolic effects.
Here we examined whether macrophage aP2 influences foamcell formation and the development of atherosclerosis independent of the effects of aP2 on insulin resistance and plasma lipids. Using two different models, Apoe -/-mice intercrossed with Ap2 -/-mice and the bone-marrow transplantation (BMT) model in which Ap2 -/-Apoe -/-mice are donors to recipient Ap2 +/+ Apoe -/-mice, we demonstrate that aP2-deficient macrophages provide significant protection against atherosclerosis in the ApoE-deficient model in the absence of differences in glucose and lipid metabolism. 

Metabolism and atherosclerosis in Ap2
-/-Apoe -/-mice Feeding C57BL/6 mice a high-fat diet promotes the development of obesity and insulin resistance 19 , which could impact the development of atherosclerosis 20 . We therefore initially used ApoE-deficient mice, which on a normal chow diet develop spontaneous atherosclerotic lesions that are largely independent of obesity, hyperglycemia and hyperinsulinemia. To analyze the role of aP2 in atherosclerotic lesion formation, we intercrossed Ap2 -/-mice with ApoE-deficient mice. At 4 weeks, we divided littermates into an experimental group of Ap2
Apoe
-/-(n = 7) and a control group of Ap2
Apoe -/-(n = 7) mice and fed them a regular chow diet (< 4.5% fat) for 14 weeks. After insulin tolerance tests and steady-state biochemical measurements, we analyzed the extent of aortic atherosclerosis at 18 weeks. After a fourhour fast, total serum cholesterol (445 ± 36 versus 478 ± 12; mg/dl ± s.e.m.) and triglyceride (142 ± 27 versus 193 ± 13; mg/dl ± s.e.m.) levels were elevated as a result of ApoE deficiency in both Ap2 +/+ and Ap2 -/-groups, respectively, without significant differences between genotypes. In addition, serum-glucose levels did not differ significantly between the experimental and control mice (117 ± 5.9 and 126.3 ± 13; mg/dl ± s.e.m.; P = 0.53). There was a reduction in total cholesterol, triglyceride and glucose, but not insulin levels in the Ap2
-/-group compared with Ap2
Apoe -/-controls after 24 hours fasting (data not shown). Insulin tolerance studies showed that insulin sensitivity did not differ between the male Ap2 -/-
-/-and Ap2
-/-mice (Fig. 1a) . We saw similar results in the females, except that insulin tolerance tests indicated a small improvement in the Ap2
-/-mice compared with Apoe -/-controls (Fig. 1b) . These data showed that except for a small change in insulin sensitivity in the females, the steady state metabolic status of these mice was similar.
All of the mice developed moderate, fatty streak lesions, consisting predominantly of macrophage-derived foam cells, as determined by immunocytochemistry using the monoclonal antibody against mouse macrophages 21 , MOMA-2 (Fig. 1c, upper panels) . The macrophage-derived foam cells stained strongly positive for aP2 in the lesions of the Ap2 (Fig. 1c, lower panels) . Quantitative analysis of the proximal aorta revealed that the mean atherosclerotic lesion area in Ap2
males was reduced by 66% compared with Ap2
-/-males (36,334 ± 3,492 versus 107,815 ± 11,144; µm 2 /section ± s.e.m.; P < 0.0014; Fig. 1d ). A similar reduction (87.6%) was found by en face analysis of the extent of atherosclerosis in the entire aorta in Ap2
-/-males compared with Ap2
-/-controls (0.60 ± 0.15 versus 0.074 ± 0.42; percent ± s.e.m.; P < 0.005; Fig. 1e ). Thus, in the setting of a normal chow diet, male ApoE-deficient mice lacking aP2 were protected from the development of macrophage-derived foam cells and atherosclerosis. In a separate experiment, the extent of atherosclerosis in the proximal aorta was reduced by 35% in male and by 26% in female Ap2
-/-mice fed the Western diet for 14 weeks compared with Ap2
-/-controls (P < 0.0024 and P < 0.006, respectively; data not shown).
FABP expression and function in macrophages
Given that atherosclerotic lesions showed strong presence of aP2 and the differences in atherosclerosis occurred in the absence of significant metabolic alterations, macrophage aP2 expression might be responsible for the observed differences in atherosclerosis. We therefore investigated aP2 expression and regulation in primary isolated macrophages and macrophage cell lines. In both THP-1 and U-937 human monocyte/macrophage cell lines, we did not detect aP2 expression in resting cells but did so after stimulation by PMA (phorbol 13-myristate 12-acetate) to induce differentiation ( Fig. 2a and b) . Similarly, primary human monocytes did not express aP2 protein, but we observed high levels upon stimulation with PMA (Fig. 2d) . In contrast, we did not detect aP2 expression by northern-blot analysis of resting or stimulated EL4 T-cell or M12 Bcell lines (data not shown). The keratinocyte FABP, mal1, which is the second isoform expressed in adipocytes, was also present in these cells and was regulated in an essentially identical manner upon PMA stimulation, although low levels were detectable in the resting state in THP-1 and U-937 cell lines ( Fig. 2a and b) . Expression of both aP2 and mal1 was also observed in isolated peritoneal mouse macrophages. Unlike the compensatory regulation in adipocytes, mRNA encoding mal1 did not appear to be significantly upregulated in Ap2 -/-primary macrophages (Fig. 2c) . We then investigated whether the regulatory elements that direct expression of aP2 in adipocytes are sufficient to confer expression in macrophages of transgenic mice. For this we used three independent lines expressing genes encoding uncoupling protein (UCP)-1, We next investigated whether aP2 deficiency has functional consequences in macrophage biology that might be relevant to the development of atherosclerosis. We first determined the expression of several inflammatory cytokines, including TNF-α, interleukin (IL)-1β and IL-6 in Ap2 -/-macrophages and wild-type controls. In the resting state, expression of these cytokines was significantly reduced in the aP2-deficient macrophage cell lines compared with Ap2 +/+ controls ( Fig. 3a) . Moreover, whereas an increase in TNF-α, IL-1β, and IL-6 expression was evident in the wild-type cells upon PMA stimulation, we observed no changes in the Ap2 -/-cells, demonstrating a reduced inflammatory capacity of Ap2 -/-macrophages ( Fig. 3a) .
To examine the potential function of aP2 in macrophage lipid deposition, cholesterol ester accumulation was assayed in acetylated low-density lipoprotein (Ac-LDL)-loaded macrophages derived from wild-type and Ap2 -/-mice. Lipids extracted from cells were assayed using a Nile Red fluorescent-lipid thin-layer chromatography (TLC). Ap2 -/-macrophages responded to Ac-LDL loading with 37% less accumulation of cholesterol ester compared with the Ap2 +/+ controls (P < 0.001; Fig. 3b ). In the absence of lipid loading, the cholesterol ester levels in the Ap2 -/-cells were 29% lower than in Ap2 +/+ cells (P < 0.01). We also evaluated the levels of aP2 and mal1 protein expression in the Ap2 -/-and wild-type macrophages. Under the conditions of the lipid accumulation studies, the aP2 protein level in the wild-type line (2 ng/µg cell protein) was approximately 22% that of mal1 (9 ng/µg). In the Ap2 -/-line, aP2 was not detectable and mal1 was 20.9 ng/µg. Exposure to Ac-LDL did not affect the expression levels of either (Fig. 3b, lower panel) . These results indicate that genetic elimination of aP2 significantly decreased intracellular cholesterol ester accumulation in macrophages despite the presence of substantial amounts of mal1 protein. We also determined cytokine production from these cells under the same experimental conditions. These experiments demonstrated a strong reduction in the capacity of Ap2 -/-cells to secrete TNF-α, monocyte chemotactic protein (MCP)-1, and IL-6 proteins compared with wild-type controls (Fig. 3c ).
Bone-marrow transplantation studies
BMT studies in gene-targeted mice have been a powerful tool to examine the contribution of various genes expressed by macrophages to foam-cell formation and atherogenesis [22] [23] [24] [25] . We therefore created Apoe -/-mice chimeric for macrophage aP2 expression using BMT to determine the contribution of macrophage aP2-deficiency in atherogenesis. Ten-week-old male Apoe -/-mice were lethally radiated (9 Gy) and transplanted with either Ap2
Apoe
-/-(experimental group, n = 10) or Ap2
-/-(control group, n = 8) bone marrow. Similarly, 10-week-old female Apoe -/-mice were lethally radiated and transplanted with either Ap2
-/-(experimental group, n = 8) or Ap2
-/-(control group, n = 11) bone marrow. The transplanted mice were fed a standard chow diet (< 4.5% fat) for 13 weeks. We observed no significant differences in serum levels of glucose, cholesterol or triglycerides between the experimental and control groups in either experiment at 8 or 13 weeks after transplantation (Table 1) . Moreover, the distribution of cholesterol among the serum lipoproteins as determined by size exclusion chromatography did not differ significantly between the experimental and control groups in either experiment (Fig. 4a) . Finally, insulin tolerance tests showed that insulin sensitivity did not differ between the two groups (data not shown). Therefore, the lack of macrophage aP2 expression had no impact on fasting serum-glucose and -lipid levels or lipoprotein profiles under these dietary conditions.
Thirteen weeks after transplantation, the extent of atherosclerosis in the proximal aortas of the transplanted Apoe -/-mice was determined. Staining of cross-sections of the proximal aorta with Oil Red O revealed fatty streak lesions, which in the males consisted almost exclusively of macrophage-derived foam cells, as determined by immunocytochemical staining with MOMA-2 (Fig. 4b) . Immunocytochemical analysis of serial sections of the proximal aorta by staining with MOMA-2 for mouse macrophages (Fig. 4b,  upper panels) , or the aP2 protein (Fig. 4b , lower panels) revealed 
Discussion
Previous studies have demonstrated that deficiency of aP2, a downstream target of PPAR-γ, predominantly affects adipocytes and contributes to improved systemic glucose and lipid metabolism in the setting of dietary or genetic obesity 7, 8 . Here, we demonstrate that aP2 is also strongly expressed in macrophages and modulates their biological responses. Total and macrophagespecific aP2 deficiencies led to a striking protection from the development of atherosclerosis in the Apoe -/-model. Based on these data, a potential mechanism underlying the metabolic syndrome emerges from coordinated modulation of the metabolic status of adipocytes and the metabolic or inflammatory status of macrophages through pathways common to both cell types.
The gene encoding aP2 is expressed at high levels in mouse and human macrophages upon activation in vitro and in macrophages associated with atherosclerotic lesions in vivo, raising the possibility that it might impact the macrophage inflammatory response and foam-cell formation. As in adipocytes, production of TNF-α is greatly reduced in Ap2 -/-macrophages compared with wild-type controls 7 . Other inflammatory cytokines such as IL-1β and IL-6 are also suppressed in Ap2 -/-macrophages. Moreover, Ap2
-/-macrophages display significantly decreased intracellular cholesterol ester accumulation in vitro and secrete highly reduced quantities of TNF-α, MCP-1 and IL-6 upon exposure to modified lipoprotein. These results indicate that aP2 has a significant role in two important aspects of macrophage biology that are highly relevant to the pathogenesis of atherosclerosis. mal1, a close relative of aP2, presents an expression pattern similar to aP2. However, whereas the expression of mal1 mRNA in Ap2 -/-adipocytes is greatly enhanced, compensatory regulation in Ap2 -/-macrophages is mild. Hence, it will be important to determine the impact of mal1 and combined aP2/mal1 deficiency in metabolic regulation and atherosclerosis. Finally, macrophage aP2 expression is controlled with the same promoter/enhancer elements that confer expression in adipocytes; this might have important implications in the assessment of many transgenic lines generated with the 5.4-kb aP2 promoter/enhancer. Both macrophages and adipocytes are sites for active lipid metabolism and signaling. Therefore, it is not surprising that FABPs have a strong impact on the biology of these cells. This is likely to involve many aspects of lipid metabolism in both cell types including transport of lipids and shuttling them to specific metabolic or signaling pathways. Recent studies with other isoforms have indicated potential regulation of nuclear hormone receptor activity in the liver through direct transportation of lipid and xenobiotic ligands 26 . Regulation of macrophage ACAT activity [27] [28] [29] or the availability of FA for esterification with cholesterol might also be altered by FABPs. Alternatively, FABPs could impact the rates of transport through quantitative or functional alterations in fatty-acid transporters or scavenger receptors. Further studies will be required to address these possibilities.
A critical question is whether the function of aP2 in the macrophage is sufficient to modulate development of atherosclerosis in a way that is distinguishable from the metabolic consequences of aP2 deficiency. We have taken several steps to address this question. First, we studied the effect of aP2 deficiency on the development of atherosclerosis in Apoe -/-mice on normal chow diet. On this diet, ApoE-deficient mice exhibit severe hypercholesterolemia and spontaneous atherosclerotic lesions in the absence of significant changes in body weight or serum levels of glucose or insulin. Under these conditions, male Ap2 -/-Apoe -/-mice, despite severe hypercholesterolemia, developed 66% less atherosclerosis in cross-sections of the proximal aorta and 86% smaller lesions by en face analysis of the extent of lesions in the entire aorta compared with control Ap2 +/+ Apoe -/-mice. These reductions in the extent of atherosclerosis occurred in the absence of significant changes in serum-lipid, -glucose or -insulin levels, supporting the hypothesis that aP2 expression contributes to atherosclerosis independent of its established role in glucose and lipid metabolism.
Second, we generated macrophage-restricted aP2 deficiency through BMT experiments to examine the hypothesis that macrophage aP2 expression promotes atherogenesis independent of its expression by adipocytes. Male Apoe -/-mice reconstituted with Ap2 -/-macrophages had a 43% and 49% reduction in lesion area compared with those reconstituted with Ap2 +/+ cells, as assessed by both lesion size in cross sections of the proximal aorta and in the entire aorta en face, respectively. As expected, the extent of atherosclerosis was greater in the proximal aortas of female ApoE-deficient transplanted mice than in the males, and the reduction in vascular lesions in female Ap2
-/-mice at this site was not statistically significant. Although this observation indicates a potential gender difference regarding the effect of aP2 expression in atherosclerosis, we think that it most likely reflects the fact that the lesions in the proximal aorta of the females were more advanced. These include intermediate lesions with smooth muscle cell involvement, indicating that the contribution of macrophage aP2 expression might be lessened in the setting of more advanced lesions. In the whole aorta, a significant 48% reduction in mean lesion area was evident in female Ap2
Apoe
-/-mice compared with female Ap2
→ Apoe -/-mice. This may be explained by the fact that mice develop atherosclerotic lesions first in the proximal aorta and the lesions progress distally, resulting in more advanced lesions in the proximal than the distal aorta 30 . Moreover, in response to 14 weeks on the Western-type diet, female Apoe
Ap2
-/-mice show reduced atherosclerosis in the proximal aorta compared with Apoe
-/-con-
ARTICLES
Macrophage studies. PBMCs were prepared from healthy donors as described 38 and were incubated overnight in RPMI medium + 5% FBS to spontaneously differentiate into macrophages. THP-1 (ATCC #TIB 202) and U-937 (ATCC #CRL-1593.2) human monocytic leukemia cell lines were grown in RPMI with 5% FBS and differentiated by 25 or 100 nM PMA into macrophages. Immortalized Ap2 +/+ and Ap2 -/-murine macrophage cell lines were generated in our laboratory by a modification of a described procedure 39 . Primary macrophages are isolated from the peritoneal cavity and were incubated with the indicated reagents for 24 hours. Ap2 +/+ and Ap2 -/-mouse macrophage cell lines were grown to near confluence in 12-well plates in RPMI-1640 with 5% FBS. Supernatants were collected after 72 h of treatment with 50 µg/ml Ac-LDL (Biomedical Technologies, Stoughton, Massachusetts) and cytokine levels were determined by commercially available ELISA systems (TNF-α from R&D, Minneapolis, Minnesota; IL-6 and MCP-1 from PharMingen, San Diego, California). Macrophage cell lines were cultured and lipids were extracted from the cells for TLC analysis as described 40 .
Immunoblots were conducted with rabbit antibodies against human recombinant aP2 and mal1 as described 10 . trols, indicating that the effects of aP2 on atherosclerosis are not gender specific. These results demonstrate a significant role for macrophage aP2 in atherogenesis independent of its expression in adipocytes and its role in glucose and lipid metabolism.
Taken together with the previous observations regarding the impact of aP2 on glucose and lipid metabolism, our data support an important role for aP2 in understanding the molecular basis of metabolic syndrome via its coordinated action on both metabolic and inflammatory responses. These findings should provide further insights into the molecular mechanisms leading to these diseases and generate opportunities for the development of a novel class of therapeutic modalities to treat them.
Methods
Animal procedures. Mice homozygous for inactivation of Ap2 were backcrossed 12 generations into the C57BL/6 background 8, 10 . These Ap2 -/-mice were intercrossed with the ApoE-deficient mice also in the C57BL/6 background to generate mice heterozygous at both loci. These Ap2 
Apoe
Apoe -/-mice described above. Recipient mice were derived from an established colony at our mouse facility of ApoE-deficient mice on the C57BL/6 background 22, 31 . Mice were fed standard chow with 4.5% fat (PMI Feeds, St. Louis, Missouri) or Western diet (diet #TD88137, Harland Teklad, Madison, Wisconson). UCP1 and agouti transgenic mice were provided by L. Kozak. Transgenic mice expressing a membrane-bound form of TNF-α driven by the aP2 promoter/enhancer in the TNF-α-deficient background were generated in one of our laboratories (Harvard). Animal care and experimental procedures were performed under approval from the Animal Care Committees of Vanderbilt and Harvard Universities.
Bone-marrow transplantation. 1 week before and 2 weeks following BMT, 100 mg/L neomycin and 10 mg/L polymyxin B sulfate (Sigma) were added to the acidified water. Bone marrow was collected from donor mice by flushing femurs with RPMI 1640 media (GIBCO, Grand Island, New York) containing 2% FBS and 5 U/ml heparin (Sigma). Recipient mice were lethally irradiated (9 Gy) by a cesium gamma source. 4 hours later, 5-10 × 10 6 bone-marrow cells in 0.3 ml were transplanted by tail-vein injection as described 22, 32 . Serum measurements and insulin tolerance tests. Mice were fasted for either 4 h during day or 24 h overnight and blood samples were collected by retro-orbital venous plexus puncture under isoflurane anesthesia (IsoVet, Schering-Plough, Union, New Jersey). Serum was separated by centrifugation and 1 mM phenylmethylsulfonyl fluoride was added (Sigma). The serum total cholesterol and triglycerides were determined using Sigma kit #352 and kit #339 adapted for microtiter plate assay as described 33 . Blood glucose concentrations were determined on 5 µl whole blood by using gluco-analyser blood glucose strips (Medisense, Bedford, Massachussetts). Steady-state insulin concentrations were determined with a commercially available radioimmunoassay (Linco, St. Charles, Missouri). Lipoprotein assays were performed as described 30 . Insulin tolerance tests (0.5 IU/kg) were performed on conscious mice following a 6-h fast as described 7, 34, 35 .
Immunocytochemistry and quantification of arterial lesions. To detect macrophages and the aP2 protein in arterial lesions, 5-µm serial cryosections of the proximal aorta were incubated with either a polyclonal rabbit antiserum against mouse aP2 (gift of D. Bernlohr) or rat antibody against mouse macrophages 21 , MOMA-2 (Accurate, Westbury, New York) as described 25 . For quantification of arterial lesions, aortas were pinned out in an en face preparation as described 30, 36 . 10-µm thick cryosections of the proximal aorta were stained with Oil Red O and counterstained with hematoxylin, as described 23, 37 . Quantitative analysis of lipid-stained lesions was performed using an Imaging System KS 300 (Release 2.0; Kontron Electronik GmbH, Eden Prairie, Minnesota). Color threshold was used to delimit the Oil-Red-O-stained lesion area that was measured as squared microns per mouse.
